Non-vitamin K Oral Anticoagulants in Cardioversion

Non-vitamin K oral anticoagulants (NOAC) have been shown to be safe and effective alternatives to warfarin for stroke prevention in patients with nonvalvular AF (NVAF). There are yet limited real life data on outcomes following elective cardioversion in AF patients treated with NOACs. The aim of this study is to investigate the complications and the use of NOACs in AF patients undergoing cardioversion.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Atrial Fibrillation Arrhythmias, Cardiac Cardiovascular Diseases Heart Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

AF patients undergoing cardioversion

Exclusion criteria

Treatment and study plan

Primary outcomes

Incidence and predictors of thromboembolic complications

Time frame: 31 days after cardioversion of persistent AF
Incidence and predictors of bleeding

Time frame: 31 days after cardioversion of persistent AF

Secondary outcomes

Number of recurrence of AF

Time frame: 31 days after cardioversion of persistent AF
Hemodynamic complications of cardioversion

Time frame: 31 days after cardioversion of persistent AF

Sponsors and collaborators

Lead sponsor

Helsinki University Central Hospital

Other

Collaborators

University of Turku

Registry information

Official study title

Non-vitamin K Oral Anticoagulants in Cardioversion of Atrial Fibrillation. FinCV3

Acronym: FinCV3

Important dates

Study start: 2011
Primary completion: 2015
Study completion: 2016
First posted: Sep 22, 2016
Registry last updated: Sep 22, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed